Publications

Abstract# 2144: Do allergies improve survival from pancreatic cancer?

S Olson, J Chou, E Ludwig-Miller, E O’Reilly, P Allen, W Jarnagin, ...

Accomplishments in 2008 in the management of localized pancreatic cancer

EM O’Reilly, MP Lutz, P Neuhaus

Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer

SR Murugesan, CR King, R Osborn, WR Fairweather, EM O'reilly, ...

Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement

RA Abrams, AM Lowy, EM O’Reilly, RA Wolff, VJ Picozzi, PWT Pisters

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment

PA Philip, M Mooney, D Jaffe, G Eckhardt, M Moore, N Meropol, L Emens, ...

Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers

FD Huitzil-Melendez, EM O'Reilly, A Duffy, GK Abou-Alfa

Intensity-modulated Radiotherapy and Concurrent Chemotherapy for Locally Advanced and Resected Pancreatic Cancer: Evaluation of Toxicity and Disease Control Outcomes

AJ Wu, LM Jacks, Z Zhang, AY Ho, EM O'Reilly, AV Kowalski, BH Kim, ...

Lack of splenic uptake of In-111 pentetreotide due to splenic embolization

Y Lu, EM O’Reilly, JA Carrasquillo

M1289 Family History of Certain Cancers Is Not Associated with Younger Age At Diagnosis of Pancreatic Adenocarcinoma

E Ludwig, AS Reiner, N Chung, J Simon, S Bayuga, EM O'Reilly, PJ Allen, ...

Pancreatic adenocarcinoma in a young patient population—12‐year experience at Memorial Sloan Kettering Cancer Center

A Duffy, M Capanu, P Allen, R Kurtz, SH Olson, E Ludwig, DS Klimstra, ...

Pancreatic adenocarcinoma: new strategies for success

EM O’Reilly

Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors

GY Ku, EM O'Reilly, LB Saltz, D Schrag, RG Maki, DP Kelsen, DH Ilson

Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer

WP Tew, D Radovich, E O’Reilly, G Schwartz, D Schrag, LB Saltz, ...

Targeted therapies for pancreatic adenocarcinoma.

M Lowery, EM O'Reilly

A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors

AN Tse, DS Klimstra, M Gonen, M Shah, T Sheikh, R Sikorski, R Carvajal, ...

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma

A Duffy, J Kortmansky, GK Schwartz, M Capanu, S Puleio, B Minsky, ...

A phase II study of docetaxel (D) followed by flavopiridol (F) in advanced, gemcitabine-refractory pancreatic cancer (PC)

RD Carvajal, MA Shah, A Tse, R Lefkowitz, DP Kelsen, GK Schwartz, ...

A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603

EM O’Reilly, D Niedzwiecki, DR Hollis, TS Bekaii-Saab, T Pluard, A Duffy, ...

ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon

VJ Picozzi, RA Abrams, LW Traverso, EM O’Reilly, E Greeno, RC Martin, ...

Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis

A Duffy, J Shia, D Klimstra, L Temple, EM O'Reilly

Combination of human tumor necrosis factor alpha (hTNFα) gene delivery with gemcitabine is effective in models of pancreatic cancer

S Murugesan, L Wei, R Osborn, M Thornton, C King, E O'Reilly

Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreatic cancer

EM O'reilly, GK Abou-Alfa

Correlation of history of tobacco consumption and type of k-ras mutation in patients (pts) with pancreatic adenocarcinoma (PC)

DP Kelsen, EM O'Reilly, FDH Melendez, J Zheng, M Capanu, A Duffy, ...

Current management of advanced hepatocellular carcinoma

GK Abou-Alfa, FD Huitzil-Melendez, EM O’Reilly, LB Saltz

Gallbladder cancer (GBC): 10‐year experience at memorial Sloan‐Kettering cancer centre (MSKCC)

A Duffy, M Capanu, GK Abou‐Alfa, D Huitzil, W Jarnagin, Y Fong, ...

Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection

I Endo, M Gonen, AC Yopp, KM Dalal, Q Zhou, D Klimstra, M D'Angelica, ...

Pancreatic adenocarcinoma (PAC) in a younger patient population: 10-year experience at Memorial Sloan-Kettering Cancer Center (MSKCC)

A Duffy, M Capanu, P Allen, R Kurtz, E Ludwig, S Olson, D Klimstra, ...

Pancreatic Cancer

J Abbruzzese, R Kurzrock, D McConkey, K Xie, S Safe, G Gallick, D Evans, ...

Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix

LH Tang, J Shia, RA Soslow, D Dhall, WD Wong, E O'Reilly, J Qin, P Paty, ...

Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma

A Duffy, J Shia, FD Huitzil-Melendez, Y Fong, EM O'Reilly

Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer

GY Ku, DH Ilson, LH Schwartz, M Capanu, E O’Reilly, MA Shah, ...

What is the optimal treatment of localized pancreatic adenocarcinoma?

A Duffy, EM O'Reilly

A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression

Vijayvargia R, May MS, Fondell JD

Cytotoxic therapy for advanced pancreatic adenocarcinoma

EM O’Reilly, GK Abou-Alfa

Gallbladder cancer (GBC): 10-year experience at memorial Sloan-Kettering Cancer Centre (MSKCC)

A Duffy, M Capanu, GK Abou-Alfa, D Huitzel, P Williams, W Jarnagin, ...

Inoperable Pancreatic Cancer: Standard of Care The Article Reviewed

A Duffy, EM O'Reilly

Key Challenges in Managing Advanced Pancreatic Cancer.

A Duffy, EM O'Reilly

Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors

AN Tse, R Carvajal, M Shah, H Dials, M Fogel, E O’Reilly, K Chung, ...

Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors

MN Fornier, D Rathkopf, M Shah, S Patil, E O'Reilly, AN Tse, C Hudis, ...

Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study

PA Philip, J Benedetti, C Fenoglio-Preiser, M Zalupski, H Lenz, E O'reilly, ...

Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): Multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial …

FD Huitzil, M Capanu, G Jacobs, W Smith, E O’Reilly, M Shah, ...

Section III: Treatment of advanced gastrointestinal cancers

HS Hochster, EM O’Reilly, JA Ajani, AP Venook

Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology

RM Goldberg, JL Marshall, JA Ajani, PA Philip, EM O’Reilly, AP Venook

A phase I clinical and pharmacokinetic study of flavopiridol administered concurrently with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for advanced solid tumors

RD Meng, RD Carvajal, AN Tse, MA Shah, H Dials, D Brukner, ...

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma

MA Shah, RK Ramanathan, DH Ilson, A Levnor, D D'Adamo, E O'Reilly, ...

Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer

KY Chung, B Minsky, D Schrag, E O’Reilly, D D’Adamo, E Hollywood, ...

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

GK Abou-Alfa, R Letourneau, G Harker, M Modiano, H Hurwitz, ...

A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma.

DA Deming, AL Stella, KD Holen, G Ku, EM O'Reilly

A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancer

D Rathkopf, M Fornier, MA Shah, J Kortmansky, E O’Reilly, J Winkelmann, ...

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

MA Shah, J Kortmansky, M Motwani, M Drobnjak, M Gonen, S Yi, ...